|
|
Lars Johan Nissen, Renhai Cao, Eva-Maria Hedlund, Zongwei Wang, Xing Zhao, Daniel Wetterskog, Keiko Funa, Ebba Bråkenhielm, Yihai Cao
J Clin Invest. 2007;
117(10):2766
doi:10.1172/JCI32479
Abstract |
Full text
| PDF
| Supplemental material

T
umors produce multiple growth factors, but little is known about the interplay between various angiogenic factors in promoting tumor angiogenesis, growth, and metastasis. Here we show that 2 angiogenic factors frequently upregulated in tumors, PDGF-BB and FGF2, synergistically promote tumor angiogenesis and pulmonary metastasis. Simultaneous overexpression of PDGF-BB and FGF2 in murine fibrosarcomas led to the formation of high-density primitive vascular plexuses, which were poorly coated with pericytes and VSMCs. Surprisingly, overexpression of PDGF-BB alone in tumor cells resulted in dissociation of VSMCs from tumor vessels and decreased recruitment of pericytes. In the absence of FGF2, capillary ECs lacked response to PDGF-BB. However, FGF2 triggers PDGFR-α and -β expression at the transcriptional level in ECs, which acquire hyperresponsiveness to PDGF-BB. Similarly, PDGF-BB–treated VSMCs become responsive to FGF2 stimulation via upregulation of FGF receptor 1 (FGFR1) promoter activity. These findings demonstrate that PDGF-BB and FGF2 reciprocally increase their EC and mural cell responses, leading to disorganized neovascularization and metastasis. Our data suggest that intervention of this non-VEGF reciprocal interaction loop for the tumor vasculature could be an important therapeutic target for the treatment of cancer and metastasis.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(59)
| Title and authors |
Publication |
Year |
FGF Receptor Inhibitors: Role in Cancer Therapy
Gennaro Daniele, Jesus Corral, L. Rhoda Molife, Johann S. Bono
|
Curr Oncol Rep
|
2012 |
Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer
Karen L. Reckamp
|
Cancer Letters
|
2012 |
Novel targets for VEGF-independent anti-angiogenic drugs
Marco Petrillo, Giovanni Scambia, Gabriella Ferrandina
|
Expert Opin. Investig. Drugs
|
2012 |
Pericytes on the Tumor Vasculature: Jekyll or Hyde?
Keith D. Barlow, Anne M. Sanders, Shay Soker, Suleyman Ergun, Linda J. Metheny-Barlow
|
Cancer Microenvironment
|
2012 |
Prognostic Impact of Angiogenic Markers in Non–Small-Cell Lung Cancer is Related to Tumor Size
Tom Donnem, Sigve Andersen, Samer Al-Saad, Khalid Al-Shibli, Lill-Tove Busund, Roy M. Bremnes
|
Clinical Lung Cancer
|
2011 |
Molecular indicators of non-sentinel node status in breast cancer determined in preoperative biopsies by multiplexed sandwich immunoassays
Georg Sauer, Nicole Schneiderhan-Marra, Rainer Muche, Karin Koretz, Cornelia Kazmaier, Rolf Kreienberg, Thomas Joos, Helmut Deissler
|
J Cancer Res Clin Oncol
|
2011 |
bFGF and PDGF-BB have a synergistic effect on the proliferation, migration and VEGF release of endothelial progenitor cells
Guo Sufen, Yang Xianghong, Cheng Yongxia, Pan Qian
|
Cell. Biol. Int.
|
2011 |
Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway
Domenico Ribatti
|
Cancer Treatment Reviews
|
2011 |
FGF-dependent regulation of VEGF receptor 2 expression in mice
Masahiro Murakami, Loc T. Nguyen, Kunihiko Hatanaka, William Schachterle, Pei-Yu Chen, Zhen W. Zhuang, Brian L. Black, Michael Simons
|
J. Clin. Invest.
|
2011 |
Tyrosine kinases in inflammatory dermatologic disease
Ricardo T. Paniagua, David F. Fiorentino, Lorinda Chung, William H. Robinson
|
Journal of the American Academy of Dermatology
|
2011 |
|